Synergistic Rifabutin and Colistin Reduce Emergence of Resistance When Treating Acinetobacter baumannii.

Autor:	Cheng J; Department of Molecular Microbiology and Immunology, Keck School of Medicine at USC, Los Angeles, California, USA., Yan J; Department of Molecular Microbiology and Immunology, Keck School of Medicine at USC, Los Angeles, California, USA., Reyna Z; Department of Molecular Microbiology and Immunology, Keck School of Medicine at USC, Los Angeles, California, USA., Slarve M; Department of Molecular Microbiology and Immunology, Keck School of Medicine at USC, Los Angeles, California, USA., Lu P; Department of Molecular Microbiology and Immunology, Keck School of Medicine at USC, Los Angeles, California, USA., Spellberg B; Los Angeles County-USC (LAC+USC) Medical Center, Los Angeles, California, USA., Luna B; Department of Molecular Microbiology and Immunology, Keck School of Medicine at USC, Los Angeles, California, USA brian.luna@usc.edu.
Jazyk:	angličtina
Zdroj:	Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2021 Mar 18; Vol. 65 (4). Date of Electronic Publication: 2021 Mar 18 (Print Publication: 2021).
DOI:	10.1128/AAC.02204-20
Abstrakt:	Recently, we reported rifabutin hyperactivity against Acinetobacter baumannii We sought to characterize potential interactions between rifabutin and colistin, the last-resort drug for carbapenem-resistant infections. Rifabutin and colistin were synergistic in vitro and in vivo , and low-dose colistin significantly suppressed emergence of resistance to rifabutin. Thus, this combination is a promising therapeutic option for highly resistant A. baumannii infections. (Copyright © 2021 Cheng et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu